GAMIDA CELL LTD (GMDA)       1.62  +0.07 (+4.52%)

1.62  +0.07 (+4.52%)

IL0011552663 - Common Stock - After market: 1.55 -0.07 (-4.32%)

GAMIDA CELL LTD1.62

NASDAQ:GMDA (1/27/2023, 7:11:08 PM)+0.07 (+4.52%)

After market: 1.55 -0.07 (-4.32%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) N/A N/A
Ins Owners 1.13% Inst Owners 31.96%
Market Cap 120.50M Shares 74.38M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 83.33
IPO 10-26 2018-10-26

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GMDA Daily chart

Company Profile

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Company Info

GAMIDA CELL LTD

PO Box 34670

JERUSALEM 95484

P: 97226595666.0

CEO: Julian Adams

Employees: 166

Website: http://www.gamida-cell.com

GMDA News

News Image2 months ago - Gamida Cell Ltd.Gamida Cell Announces Closing of $25 Million Financing With HighbridgeNews Image2 months ago - Gamida Cell Ltd.Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor ConferencesNews Image2 months ago - Seeking AlphaGMDA stock drops as FDA extends review for lead candidate (NASDAQ:GMDA)

Israel-based biotech Gamida Cell Ltd. (GMDA) lost ~21% in the pre-market trading Tuesday after announcing that the U.S

News Image2 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday morning!

News Image2 months ago - Gamida Cell Ltd.Gamida Cell Provides Regulatory Update on OmidubicelNews Image3 months ago - Gamida Cell Ltd.Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

GMDA Twits

Here you can normally see the latest stock twits on GMDA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example